$0.0001
0[0.00%]
At close: Apr 18
Kaleido Biosciences
(OTCEM:KLDO)Kaleido Biosciences Stock (OTC:KLDO), Analyst Ratings, Price Targets, Predictions
Kaleido Biosciences Inc has a consensus price target of $8.9, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from Chardan Capital, Chardan Capital, and Chardan Capital on April 4, 2022, January 31, 2022, and November 12, 2021. With an average price target of $5.23 between Chardan Capital, Chardan Capital, and Chardan Capital, there's an implied 5233233.33% upside for Kaleido Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
JMP Securities
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kaleido Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2022 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 1699900% | Chardan Capital | Keay Nakae | $3 → $1.7 | Downgrade | Buy → Neutral | Get Alert |
| 01/31/2022 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 2999900% | Chardan Capital | Keay Nakae | $11 → $3 | Maintains | Buy | Get Alert |
| 11/12/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 10999900% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
| 11/03/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 21999900% | JMP Securities | Gobind Singh | — | Maintains | Market Outperform | Get Alert |
| 10/19/2021 | KLDO | Buy Now | Kaleido Biosciences | $0.00 | 2999900% | Morgan Stanley | Matthew Harrison | — | Downgrade | Equal-Weight → Underweight | Get Alert |
FAQ
What is the target price for Kaleido Biosciences (KLDO)?
The latest price target for Kaleido Biosciences (OTCEM: KLDO) was reported by Chardan Capital on April 4, 2022. The analyst firm set a price target for $1.70 expecting KLDO to rise to within 12 months (a possible 1699900.00% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kaleido Biosciences (KLDO)?
The latest analyst rating for Kaleido Biosciences (OTCEM: KLDO) was provided by Chardan Capital, and Kaleido Biosciences downgraded their neutral rating.
When was the last upgrade for Kaleido Biosciences (KLDO)?
There is no last upgrade for Kaleido Biosciences.
When was the last downgrade for Kaleido Biosciences (KLDO)?
The last downgrade for Kaleido Biosciences Inc happened on April 4, 2022 when Chardan Capital changed their price target from $3 to $1.7 for Kaleido Biosciences Inc.
When is the next analyst rating going to be posted or updated for Kaleido Biosciences (KLDO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kaleido Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kaleido Biosciences was filed on April 4, 2022 so you should expect the next rating to be made available sometime around April 4, 2023.
Is the Analyst Rating Kaleido Biosciences (KLDO) correct?
While ratings are subjective and will change, the latest Kaleido Biosciences (KLDO) rating was a downgraded with a price target of $3.00 to $1.70. The current price Kaleido Biosciences (KLDO) is trading at is $0.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.